Actively Recruiting
Phase 2 Study of Obinutuzumab for Non-infectious Active Cryoglobulinemic Vasculitis in Patients Unresponsive or Intolerant to Rituximab
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2026-08-31
30
Participants Needed
25
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying cryoglobulinemic vasculitis CV, a rare and serious immune system disorder that causes inflammation of blood vessels and can affect the skin, joints, kidneys, nerves, and other organs. This trial focuses on patients with active non-infectious CV who have not responded well to or cannot tolerate the current standard treatment Rituximab. The study aims to evaluate the safety and effectiveness of a different antibody treatment called Obinutuzumab in these patients. Participants will receive Obinutuzumab through an intravenous infusion at a dose of 1000 milligrams given at the start of the study and again two weeks later. This treatment is being assessed as a potential new option for CV patients who have limited choices due to resistance or intolerance to Rituximab. The trial is conducted as a single-arm study, meaning all participants receive Obinutuzumab, and it is designed as a phase 2 proof-of-concept study. During the study, participants will be monitored regularly for clinical response, side effects, and changes in disease activity using various clinical and laboratory tests over several months. Key outcomes include the rate of complete clinical response at 6 months, safety events up to 48 weeks, and longer-term measures of disease relapse and survival up to almost three years. Participants will undergo assessments including physical exams, laboratory tests, and disease activity scores to track progress and safety throughout the trial.
CONDITIONS
Brief Title
A Multicenter Phase 2 Single-arm Proof-of-concept Trial Assessing the Efficacy and Safety of Obinutuzumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Refractory or Intolerant to Rituximab
Research Team
D
David Saadoun, MD PhD
J
Jérôme Lambert, MD PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here